SCHEMBL30145335

SCHEMBL30145335

COc1ccc(-c2cccc3nc(CC(N)=O)cn23)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MARS2 Q96GW9 4/20 0.43
▸ JAK1 P23458 2/20 0.41
▸ CRHR1 P34998 2/20 0.41
▸ F10 P00742 1/20 0.39
▸ PLA2G2A P14555 3/20 0.38
▸ HSP90AA1 P07900 1/20 0.37
▸ HSP90AB1 P08238 1/20 0.37
▸ TGFBR1 P36897 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ CDC7 O00311 1/20 0.37
▸ CCNT1 O60563 1/20 0.37
▸ CSNK2A2 P19784 1/20 0.37
▸ CCNE1 P24864 1/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ CSNK1A1 P48729 1/20 0.37
▸ CSNK1D P48730 1/20 0.37
▸ CDK9 P50750 1/20 0.37
▸ CSNK2B P67870 1/20 0.37
▸ CSNK2A1 P68400 1/20 0.37
▸ DBF4 Q9UBU7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30145317 0.91 MARS2 (0.44) MARS2JAK1CRHR1MAPTMAPK1
SCHEMBL20596512 0.87 F10 (0.44) MARS2JAK1CRHR1F10MAPT
SCHEMBL20596490 0.83 MARS2 (0.42) MARS2JAK1CRHR1MAPTMAPK1
SCHEMBL20595852 0.77 CYP11B1 (0.41) CDC7DBF4
SCHEMBL30145217 0.75 ALDH1A3 (0.42) PLA2G2AHSP90AA1HSP90AB1MAPTCDC7
SCHEMBL20595596 0.75 MARS2 (0.53) MARS2JAK1CRHR1PLA2G2AMAPT
SCHEMBL20596077 0.74 HSP90AA1 (0.39) CRHR1HSP90AA1HSP90AB1MAPTCDC7
SCHEMBL20596138 0.73 MARS2 (0.79) MARS2JAK1CRHR1HSP90AA1HSP90AB1
SCHEMBL20595950 0.73 MARS2 (0.79) MARS2JAK1CRHR1HSP90AA1HSP90AB1
SCHEMBL20596076 0.71 NOD2 (0.38) HSP90AA1HSP90AB1MAPTMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them UNIVERSITY OF WASHINGTON (US) 2023-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584744-B2 Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them AARS1, EMG1, GARS1 MARS2 12/4885JAK1 1522/4885CRHR1 1725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback